Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Exelixis, Inc.    EXEL

EXELIXIS, INC.

(EXEL)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/14/2020 02/18/2020 02/19/2020 02/20/2020 02/21/2020 Date
20.77(c) 21.23(c) 21.8(c) 21.48(c) 21.09(c) Last
3 990 732 3 232 980 4 232 026 3 384 807 2 295 831 Volume
+2.57% +2.21% +2.68% -1.47% -1.82% Change
More quotes
Financials (USD)
Sales 2019 971 M
EBIT 2019 357 M
Net income 2019 304 M
Finance 2019 1 219 M
Yield 2019 -
Sales 2020 891 M
EBIT 2020 256 M
Net income 2020 235 M
Finance 2020 1 513 M
Yield 2020 -
P/E ratio 2019 21,8x
P/E ratio 2020 29,7x
EV / Sales2019 5,34x
EV / Sales2020 5,49x
Capitalization 6 408 M
More Financials
Company
Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF... 
More about the company
Surperformance© ratings of Exelixis, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on EXELIXIS, INC.
02/21EXELIXIS, INC. : annual earnings release
02/20EXELIXIS, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year..
AQ
02/12EXELIXIS : to Release Fourth Quarter and Full Year 2019 Financial Results on Tue..
BU
02/10EXELIXIS : Announces Encouraging Results for Cabozantinib in Combination With At..
BU
02/06EXELIXIS : Announces Webcasts of Investor Conference Presentations in February
BU
01/29EXELIXIS : Announces Partner Takeda Files New Drug Application in Japan for CABO..
BU
01/27EXELIXIS : Announces Results for Combination of Cabozantinib and Nivolumab With ..
AQ
01/24EXELIXIS : Announces Results for Combination of Cabozantinib and Nivolumab With ..
BU
01/13EXELIXIS, INC. : Results of Operations and Financial Condition, Financial Statem..
AQ
01/13EXELIXIS : Outlines Key Priorities and Anticipated Milestones for 2020-21, Annou..
AQ
01/12EXELIXIS : Outlines Key Priorities and Anticipated Milestones for 2020-21, Annou..
BU
01/07EXELIXIS : to Present at the 38th Annual J.P. Morgan Healthcare Conference on Ja..
BU
01/07EXELIXIS : Further Expands Prostate Cancer Cohort in Phase 1b COSMIC-021 Trial o..
BU
2019EXELIXIS : Enters into a Clinical Collaboration for Three Phase 3 Combination Tr..
BU
2019EXELIXIS : Announces Positive Results from IMspire150, the Phase 3 Trial of Atez..
AQ
More news
News in other languages on EXELIXIS, INC.
02/21EXELIXIS, INC. : Veröffentlichung des Jahresergebnisses
02/21EXELIXIS, INC. : publication des résultats annuels
2019EXELIXIS, INC. : publication des résultats annuels
2019EXELIXIS, INC. : Veröffentlichung des Jahresergebnisses
2018STOCK MARKET PARIS : "Tariff Man" a encore frappé
More news
Analyst Recommendations on EXELIXIS, INC.
More recommendations
Stock Trading Strategies
EXELIXIS, INC. - 2019
Good timing to go long again
BUY
More Stock Trading Analysis
Sector news : Bio Therapeutic Drugs
02/20Anglo American Discloses All Mine Deaths in Industry Shift--Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift -- Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift
DJ
02/20GlaxoSmithKline Invests $50 Million in Biotech Startup's Cell-Therapy Program
DJ
02/19Five Prime Therapeutics In License Agreement with Seattle Genetics
DJ
More sector news : Bio Therapeutic Drugs
Chart EXELIXIS, INC.
Duration : Period :
Exelixis, Inc. Technical Analysis Chart | EXEL | US30161Q1040 | MarketScreener
Technical analysis trends EXELIXIS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 24,68  $
Last Close Price 21,09  $
Spread / Highest target 66,0%
Spread / Average Target 17,0%
Spread / Lowest Target -9,91%
EPS Revisions
Managers
NameTitle
Michael M. Morrissey President, Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Christopher J. Senner Chief Financial & Accounting Officer, Executive VP
Gisela M. Schwab Chief Medical Officer & President-Medical Affairs
Peter Lamb Chief Scientific Officer & EVP-Scientific Strategy
Sector and Competitors
1st jan.Capitalization (M$)
EXELIXIS, INC.19.69%6 408
GILEAD SCIENCES3.11%88 181
VERTEX PHARMACEUTICALS12.49%63 855
REGENERON PHARMACEUTICALS6.30%43 886
WUXI APPTEC CO., LTD.22.35%26 379
GENMAB14.61%16 125